Table 5.
2011 EML | 2013 EML | 2015 EML | 2017 EML | 2019 EML | Treatment | 2011 Patent | 2013 Patent | 2015 Patent | 2017 Patent | 2019 Patent |
---|---|---|---|---|---|---|---|---|---|---|
Y | Y | Y | Y | Y | acetazolamide | N | N | N | N | N |
N | N | N | N | Y | diazoxide | N | N | N | N | N |
Y | N | N | N | N | glibenclamide | N | N | N | N | N |
N | Y | Y | Y | Y | gliclazide | N | N | N | N | N |
Y | Y | Y | Y | Y | glucagon | N | N | N | N | N |
Y | Y | Y | Y | Y | insulin injection (soluble) | N | N | N | N | N |
Y | Y | Y | Y | Y | intermediate-acting insulin | N | N | N | N | N |
N | Y | Y | Y | Y | latanoprost | Y | N | N | N | N |
Y | Y | Y | Y | Y | metformin | N | N | N | N | N |
Y | Y | Y | Y | Y | pilocarpine | N | N | N | N | N |
Y | Y | Y | Y | Y | timolol | N | N | N | N | N |
Y included, N not included